13 October 2023
Clinuvel Pharmaceuticals (CUV): The Bronze Age
Clinuvel (CUV) is one of very few ASX-listed biopharma companies directly commercialising novel pharmaceuticals across the US and EU in a highly profitable manner. We initiate coverage with a Buy rating and a Price Target of PT $24.00.